GTCM
HRTX icon

Gyon Technologies Capital Management’s Heron Therapeutics HRTX Stock Holding History

Gyon Technologies Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-59,569
Closed -$966K – 422
2021
Q1 		$966K Buy
+59,569
New +$1.06M 0.42% 54

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Gyon Technologies Capital Management's HRTX Position: Q2 2021 in Review

Gyon Technologies Capital Management sold out of Heron Therapeutics (HRTX) in Q2 2021, closing a stake of 59,569 shares — an estimated $966K sold.

Gyon Technologies Capital Management first reported a position in HRTX in Q1 2021 and held it in 1 quarter. The position peaked at $966K in Q1 2021. 189 funds tracked by Wall St. Rank hold HRTX as of Q2 2021.

  • Gyon Technologies Capital Management reported no remaining Heron Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 59,569 Heron Therapeutics shares in Q2 2021, an estimated $966K.
  • Gyon Technologies Capital Management first reported a position in Heron Therapeutics in Q1 2021 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Heron Therapeutics position peaked at $966K in Q1 2021.
  • 189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2021.

Based on Gyon Technologies Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.